Aleniglipron Phase 2 Body Composition Study

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed
    • Primary completion date changed from estimate of Aug 2026 to Sep 9, 2026
    • Study completion date changed from estimate of Oct 2026 to Sep 10, 2026
    • Eligibility criteria shortened, about 18 words
  2. Primary completion date: Jul 2026 to Aug 2026
    • Study completion date: Sep 2026 to Oct 2026
    • Secondary endpoints: details revised at 4 of 4 entries
    v3
  3. Trial status: Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Enrollment target: estimated 66 to confirmed 71
    • Primary completion date: Jun 2026 to Jul 2026
    • Study completion date: Oct 2026 to Sep 2026
    • Site details revised at 11 of 11 sites
  4. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.
Trial Details
NCT Number NCT07169942
Lead Sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions
(from sponsor)		 Obesity, Overweight, or Chronic Weight Management
Related terms Obesity, Overweight
Enrollment 71 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov